Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
H2 Pharma, which specializes in both generic and OTC liquid formulations, is looking to climb to the next level after receiving an equity investment from Ardian.
London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.
Zentiva has struck a new partnership to expand its already significant operations in Europe, this time in Greece with local firm Lavipharm.
After making several targeted investments aimed at enhancing its global production network, Siegfried has announced the acquisition of two manufacturing sites from Novartis in Spain. With this acquisition, the Swiss contract development and manufacturing organization is looking to create opportunities for profitable growth and achieve “critical size.”
Roche entered the year with a projected hit to revenues from multi-source biosimilar competition to its three leading biologics. However, the number was increased at the half-year mark and could be set to ratchet up further, according to management.
Akorn aims for “long-term growth and a brighter future” after exiting Chapter 11 protection that it had filed for in May 2020. After completing the sale to its lenders, the company is now operating as a private entity under the legal name, Akorn Operating Company LLC.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.